Format

Send to

Choose Destination
Bioanalysis. 2016;8(5):439-55. doi: 10.4155/bio.16.8. Epub 2016 Feb 19.

Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.

Author information

1
Mosaiques Diagnostics, Hannover, Germany.
2
Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Disease, Toulouse, France.
3
Université Toulouse III Paul-Sabatier, Toulouse, France.
4
BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.

Abstract

The recent advancements in clinical proteomics enabled identification of biomarker panels for a large range of diseases. A number of CE-MS-identified biomarker panels were verified and implemented in clinical studies. Despite multiple challenges, accumulating evidence supports the value and the need for proteome-based biomarker panels. In this perspective, we provide an overview of clinical studies indicating the added value of CE-MS biomarker panels over traditional diagnostics and monitoring methods. We outline apparent advantages of applying novel proteomic biomarker panels for disease diagnosis, prognosis, staging, drug development and patient management. Facing the plethora of benefits associated with the use of CE-MS biomarker panels, we envision their implementation into the medical practice in the near future.

KEYWORDS:

clinical proteomics; humanized biomarker panels; omic platforms; patient stratification; personalized medicine

PMID:
26891752
DOI:
10.4155/bio.16.8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center